# A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

> **NCT05653037** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Suzhou Ribo Life Science Co. Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** RBD4059
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05653037
- **Lead sponsor:** Suzhou Ribo Life Science Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-21
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653037, "A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05653037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*